Most patients discontinue GLP-1 treatments within one to two years, causing rapid weight regain and hunger rebound. This widespread abandonment turns durable post-GLP-1 maintenance, rather than initial pharmacological weight reduction, into the central problem in obesity care.
Chronic exposure to ultra-processed foods structurally impairs the duodenum's stem cells and nutrient-sensing capabilities. Endoscopically ablating the unhealthy mucosal lining permits a regenerated cellular surface to regrow, potentially resetting gut-to-brain metabolic communication without lifelong pharmacological dependency.
Newer pipeline agents and oral formulations fail to solve high drug discontinuation rates. Because the magnitude of post-treatment weight rebound is proportional to total weight lost, increasingly potent therapeutics inadvertently enlarge the clinical demand for durable maintenance solutions.
Patients typically require three to four years of GLP-1 therapy to realize tangible reductions in downstream obesity-related complications. If approximately 80 percent of recipients stop treatment within two to three years, paying for transient drug effects poses a questionable economic return.
Securing FDA Breakthrough Device designation opens specialized reimbursement routes for weight maintenance without immediate broad-market expense. Focusing launch resources exclusively on the top 100 to 200 centers managing high GLP-1 volumes enables companies to achieve profitability faster.
